AI and Cancer Research ── Bladder ── 2026-10-22

1 Bladder papers. Lead: Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial

Journals covered and how papers are chosen: see the index

Bladder cancer: treatment, trials and AI

Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial
European Urology · 2026-10-21 · Evidence: Randomized phase 3 trial (biomarker validation)
Abstract
Intravesical Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy for high-risk non–muscle-invasive bladder cancer (NMIBC), yet outcomes vary, with high-grade recurrences (HGR) occurring in up to 40% of patients at 5 yr. Persistent global BCG shortages, treatment intolerance, and the emergence of alternative therapies have intensified the need for novel biomarkers to guide management [1].
Journal IF-equivalent: 1.5 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)
Reference: [No authors listed]. Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial. European Urology. [Epub ahead of print]. doi:10.1016/j.eururo.2026.10.004.
Checked: Abstract only

← Back to this issue